Atlas Trials

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

Clinical trial NCT07091695 · COMPLETED

Trial details

NCT number
NCT07091695
Sponsor
Bristol-Myers Squibb
Status
COMPLETED
Study type
OBSERVATIONAL
Melanoma
Start date
2025-05-11
Primary completion
2025-11-06
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.